A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants.

Trial Profile

A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2014

At a glance

  • Drugs Typhoid vaccine Vi conjugate (Primary) ; Pneumococcal vaccine conjugate
  • Indications Pneumococcal infections; Typhoid
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Dec 2011 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top